会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • HIV inhibiting 5-substituted pyrimidines
    • HIV抑制5-取代嘧啶
    • US08946248B2
    • 2015-02-03
    • US11576315
    • 2005-09-29
    • Jerôme Emile Georges GuillemontJan HeeresPaulus Joannes Lewi
    • Jerôme Emile Georges GuillemontJan HeeresPaulus Joannes Lewi
    • C07D239/48A61K31/505C07D239/50
    • C07D239/48C07D239/50
    • HIV replication inhibitors of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein A is —CH2—CH2—, —CH═CH—, —C≡C—; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, R2 hydroxy, halo, C1-6alkyl, carboxyl, cyano, —C(═O)R6, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl; X1 is —NR1—, —O—, —S—, —S(═O)p—; R3 is H, C1-6alkyl, halo; R4 is H, C1-6alkyl, halo; R5 is nitro, amino, mono- and diC1-4alkylamino, aryl, halo, —CHO, —CO—R6, —COOR7, —NH—C(═O)H, —NH—C(═O)R6, —CH═N—O—R8; R6 is C1-4alkyl, amino, mono- or di(C1-4alkyl)amino or polyhaloC1-4alkyl; R7 is hydrogen, C1-6alkyl, arylC1-6alkyl; R8 is hydrogen, C1-6alkyl, aryl; p is 1 or 2; aryl is optionally substituted phenyl; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
    • 其中A是-CH 2 -CH 2 - , - CH = CH - , - C≡C-;其中A是-CH 2 -CH 2 - , - CH = CH - , - C≡C-; R1是氢,芳基,甲酰基,C1-6烷基羰基,C1-6烷基,C1-6烷氧基羰基,R2羟基,卤素,C1-6烷基,羧基,氰基,-C(= O)R6,硝基,氨基,单或二 C 1-6烷基)氨基,多卤甲基; X 1是-NR 1 - , - O - , - S - , - S(= O)p - ; R 3是H,C 1-6烷基,卤素; R4是H,C1-6烷基,卤素; R 5是硝基,氨基,单和二C 1-4烷基氨基,芳基,卤素,-CHO,-CO-R 6,-COOR 7,-NH-C(= O)H,-NH-C(= = N-O-R8; R 6是C 1-4烷基,氨基,单或二(C 1-4烷基)氨基或多卤代C 1-4烷基; R 7是氢,C 1-6烷基,芳基C 1-6烷基; R8是氢,C1-6烷基,芳基; p为1或2; 芳基是任选取代的苯基; 含有这些化合物作为活性成分的药物组合物及其制备方法。
    • 6. 发明申请
    • HIV INHIBITING 5-HETEROCYCLYL PYRIMIDINES
    • US20090181993A1
    • 2009-07-16
    • US11575818
    • 2005-09-29
    • Jerôme Emile Georges GuillemontJan HeeresPaulus Joannes Lewi
    • Jerôme Emile Georges GuillemontJan HeeresPaulus Joannes Lewi
    • A61K31/506C07D403/04C07D401/04C07D405/04C07D413/14C07D417/04A61P31/12
    • C07D405/04C07D401/04C07D403/04C07D409/04C07D413/04C07D413/14C07D417/04
    • HIV replication inhibitors of formula (I), N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a1=a2-a3=a4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b1=b2-b3=b4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; R2 is OH; halo; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; substituted amino; polyhalomethyl; polyhalomethylthio; S(═O)pR6; C(═NH)R6; R2a is CN; amino; substituted amino; optionally substituted C1-6alkyl; halo; optionally substituted C1-6alkyloxy; substituted carbonyl; —CH═N—NH—C(O)—R10; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C1-6alkenyl or C2-6 alkynyl; —C(═N—O—R8)—C1-4alkyl; R7 or —X3—R3; X1 is —NR1—, —O—, —C(═O)—, —CH2—, —CHOH—, —S—, —S(═O)p—R3 is CN; amino; C1-6alkyl; halo; optionally substituted C1-6alkyloxy; substituted carbonyl; —CH═N—NH—C(O)—R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl or C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7; —X3—R7; R4 is halo; OH; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; C3-7cycloalkyl; C1-6alkyloxy; CN; nitro; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C1-4alkyl)amino or R7; R5 is a 5- or 6-membered completely unsaturated ring system wherein 1-4 ring members are nitrogen, oxygen or sulfur; which ring may optionally be substituted and may optionally be annelated with a benzene ring; methods for their preparation and pharmaceutical compositions comprising them. The invention also relates to the use of these compounds for the prevention or the treatment of HIV infection.
    • 8. 发明申请
    • Hiv Inhibiting 1,2,4-Triazin-6-One Derivatives
    • HIF抑制1,2,4-三嗪-6-酮衍生物
    • US20090012092A1
    • 2009-01-08
    • US11573224
    • 2005-08-10
    • Georges Joseph Cornelius HoornaertAmuri KilondaJan HeeresPaulus Joannes LewiMarc Rene de JongeFrederik Frans Desire DaeyaertHendrik Maarten VinkersLucien Maria Henricus KoymansPaul Adriaan Jan JanssenFrank Xavier Jozef Herwig Arts
    • Georges Joseph Cornelius HoornaertAmuri KilondaJan HeeresPaulus Joannes LewiMarc Rene de JongeFrederik Frans Desire DaeyaertHendrik Maarten VinkersLucien Maria Henricus KoymansPaul Adriaan Jan JanssenFrank Xavier Jozef Herwig Arts
    • A61K31/53C07D253/06A61P31/18
    • C07D253/075
    • The present invention relates to HIV replication inhibitors of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein ring A and ring B represent phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; n and m are 1 to 4; R1 represents hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxyC1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl; R2 or R4 represents hydrogen; hydroxy; halo; optionally substituted C1-6alkyl; optionally substituted C2-6alkenyl; optionally substituted C2-6alkynyl; C3-7cycloalkyl; C1-6alkyloxy; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-4alkyl; polyhaloC1-4alkyloxy; polyhaloC1-4alkylthio; —S(═O)pR6; —NH—S(═O)pR6; —C(═O)R6; —NHC(═O)H; —C(═O)NHNH2; NHC(═O)R6; C(═NH)R6; or R7; R2a or R3 represents cyano; aminocarbonyl; amino; halo; NHR13; NR13R14 —C(═O)—NHR13; —C(═O)—NR13 R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; optionally substituted C1-6alkyl; optionally substituted C1-6alkyloxy; optionally substituted C1-6alkyloxyC1-6alkyl; optionally substituted C2-6alkenyl; optionally substituted C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7 or —X3—R7; X1 or X2 represents —NR1—; —NH—NH—; —N═N—; —O—; —C(═O)—; —C1-4alkanediyl-; —CHOH—; —S—; —S(═O)p—; —X4—C1-4alkanediyl-; —C1-4alkanediyl-X4—; or —C1-4alkanediyl-X4—C1-4alkanediyl-; their use as a medicine, their use for the manufacture of a medicament for the treatment or the prevention of HIV infection; their processes for preparation and pharmaceutical compositions comprising them.
    • 本发明涉及式N-氧化物的HIV复制抑制剂,其药学上可接受的加成盐,季胺或其立体化学异构形式,其中环A和环B表示苯基,吡啶基,哒嗪基,嘧啶基或吡嗪基; n和m为1〜4; R1表示氢; 芳基; 甲酰基 C 1-6烷基羰基; C 1-6烷氧基羰基; 任选取代的C 1-6烷基; 被C 1-6烷氧基羰基取代的C 1-6烷氧基C 1-6烷基羰基; R2或R4代表氢; 羟基; 光环; 任选取代的C 1-6烷基; 任选取代的C 2-6烯基; 任选取代的C 2-6炔基; C 3-7环烷基; C 1-6烷氧基; C 1-6烷氧基羰基; C 1-6烷基羰基氧基; 羧基; 氰基; 硝基 氨基; 单或二(C 1-6烷基)氨基; 多卤代C 1-4烷基; 多卤代1-4烷基氧基; 多卤代 -S(-O)p R 6; -NH-S(-O)p R 6; -C(-O)R 6; -NHC(-O)H; -C(-O)NHNH 2; NHC(-O)R 6; C(-NH)R 6; 或R7; R2a或R3表示氰基; 氨基羰基; 氨基; 光环; NHR13; NR 13 R 14 -C(-O)-NHR 13; -C( - ) - NR 13 R 14; -C(-O)-R 15; -CH-N-NH-C(-O)-R16; 任选取代的C 1-6烷基; 任选取代的C 1-6烷氧基; 任选取代的C 1-6烷氧基C 1-6烷基; 任选取代的C 2-6烯基; 任选取代的C 2-6炔基; -C(-N-O-R 8)-C 1-4烷基; R7或-X3-R7; X1或X2表示-NR1-; -NH-NH-; -N-N- -O-; -C(-O) - ; -C 1-4烷二基 -CHOH-; -S-; -S(-O)p - ; -X4-C1-4烷二基 -C 1-4烷二基-X4-; 或-C1-4烷二基-X4-C1-4烷二基; 它们作为药物的用途,它们用于制备用于治疗或预防HIV感染的药物的用途; 其制备方法和包含它们的药物组合物。